Author Interviews, Dermatology, Kidney Disease / 22.06.2020
Study Finds Novel Difelikefalin (Korsuva) Stops the Itch of Chronic Kidney Disease
MedicalResearch.com Interview with:
Gil Yosipovitch, MD, Professor
Miami Itch Center
Lennar Medical Foundation
South Miami Clinic in Coral Gables
University of Miami Health System
MedicalResearch.com: What is the background for this study?
Response: Chronic Pruritus is a common and burdensome condition in patients with end stage chronic kidney disease (CKD). It is Present at all stages of CKD, not only in patients undergoing hemodialysis (including stage 3-5 CKD). There are no approved treatments for this condition in US and Europe. CKD pruritus has significant impact on quality of life of patients with higher mortality rates due to its effect on sleep.
Studies in the last 2 decades have shown that in patients with CKD pruritus there is an imbalance between endogenous mu opioids that are over expressed to Kappa Opioids that are down regulated.
Difelikefalin (DFK) is a novel peripherally selective kappa opioid receptor (KOR) agonist. Study of IV DFK administration in hemodialysis patients has recently been published and showed significant anti Pruritic effect ( NEJM Fishbane et al. 382: 289-290, 2020).
(more…)